Publications by authors named "A David Paltiel"
Background: Long-acting, injectable cabotegravir (CAB-LA) is more effective than daily oral tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for HIV pre-exposure prophylaxis (PrEP). We aimed to estimate the maximum price premium: the greatest price markup that society should be willing to accept for CAB-LA compared with TDF-FTC among adolescent girls and young women aged 15-29 years in South Africa.
Methods: Using the Cost-effectiveness of Preventing AIDS Complications model, we simulated adolescent girls and young women (aged 15-29 years) with characteristics similar to the targeted enrolment population of the FastPrEP study in Cape Town, South Africa, to compare daily oral TDF-FTC with bimonthly CAB-LA.
Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi.
PLOS Glob Public Health
April 2025
Rotavirus is the leading cause of severe diarrhea among children under five worldwide, especially in low- and middle-income countries (LMICs). Although vaccination is the best strategy to prevent rotavirus, obstacles leading to poor vaccine effectiveness undermine its impact in LMICs. This study aimed to identify the optimal rotavirus vaccination strategy for Malawi by modeling vaccine impact and cost-effectiveness, comparing the current two-dose Rotarix vaccine schedule to two alternative vaccine delivery schedules and a next-generation neonatal vaccine (RV3-BB) from 2025-2034.
View Article and Find Full Text PDFArticle Synopsis
- The future of U.S. congressional funding for PEPFAR, which is crucial for HIV management in South Africa, is uncertain, particularly with a potential $460 million cut from the program in 2024.
- A model-based analysis predicts that if PEPFAR funding decreases to 50% or eliminates entirely, it could result in an additional 286,000 to 565,000 new HIV infections over ten years, significantly impacting life expectancy and healthcare costs.
- Sensitivity analyses suggest that countries heavily dependent on PEPFAR funding might face disproportionately higher rates of new infections and reduced survival due to funding cuts.